Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK | BSE: 532296
₹2,185.80
₹19.60
(0.90%)
As on 08-Jun-2026 12:34IST
Market cap
₹61,111 Cr
Revenue (TTM)
₹16,983 Cr
P/E Ratio
44.9
P/B Ratio
5.8
Div. Yield
0.1 %
Quality Score
3/10
Growth Score
5/10
Valuation Score
4/10
Momentum Score
9/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹1,362 Cr
-
ROE
12.6 %
-
ROCE
16.2 %
-
Industry P/E
44.87
-
EV/EBITDA
11.9
-
Debt to Equity
0
-
Book Value
₹372.5
-
EPS
₹100.1
-
Face value
1
-
Shares outstanding
282,200,809
10 Years Aggregate
CFO
₹7,139.14 Cr
EBITDA
₹17,959.50 Cr
Net Profit
₹5,447.10 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Glenmark Pharmaceuticals
| 7.4 | -7.8 | 2.9 | 37.5 | 48.8 | 28.8 | 11.1 |
|
BSE Healthcare
| 8.6 | 1.7 | 8.3 | 9.2 | 24.5 | 13.7 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Glenmark Pharmaceuticals
| 26.1 | 88.1 | 101.3 | -19.8 | 5.2 | 42.8 | -49.8 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Glenmark Pharmaceuticals
|
2,185.8 | 61,110.6 | 16,982.5 | 1,362.0 | 23.5 | 28.1 | 44.9 | 5.8 |
| 3,299.4 | 27,250.0 | 1,339.4 | 356.4 | 33.2 | 23.2 | 76.5 | 16.5 | |
| 422.8 | 16,486.7 | 2,268.6 | 150.1 | 10.6 | 5.4 | 92 | 4.2 | |
| 780.0 | 19,566.0 | 5,365.6 | 595.0 | 16.6 | 13.3 | 32.9 | 3.8 | |
| 1,431.6 | 78,174.1 | 6,812.9 | 889.9 | 19.0 | 17.6 | 88 | 14.7 | |
| 889.5 | 16,006.2 | 4,078.3 | 1,371.9 | 30.2 | 15.9 | 11.3 | 1.7 | |
| 1,739.3 | 20,522.2 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.5 | |
| 165.2 | 22,200.2 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.7 | |
| 448.1 | 17,527.3 | 3,738.7 | 316.7 | 12.5 | 7.5 | 55.3 | 3.6 | |
| 1,892.5 | 31,200.9 | 3,373.0 | 199.0 | 12.6 | 5.9 | 146.5 | 6.3 |
Shareholding Pattern
View DetailsNews & Analysis
All News
IPO update: Glenmark Life Sciences
4 min read•By Danish Khanna
1 min read•By Research Desk
2 min read•By Value Research
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic... formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India. Read more
-
Incorporated
1977
-
Chairman
Glenn Saldanha
-
Managing Director
Glenn Saldanha
-
Group
Glenmark
-
Headquarters
Mumbai, Maharashtra
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsTransfer Of Company''s Nebulizer Brand
29-May-2026Corporate Action-Board to consider Dividend
29-May-2026No News & Announcements are available.
FAQs for Glenmark Pharmaceuticals
What is the current share price of Glenmark Pharmaceuticals Ltd Today?
The share price of Glenmark Pharmaceuticals Ltd is ₹2,185.80 (NSE) and ₹2,188.15 (BSE) as of 08-Jun-2026 12:34 IST. Glenmark Pharmaceuticals Ltd has given a return of 48.83% in the last 3 years.
What is the current PB & PE ratio of Glenmark Pharmaceuticals Ltd?
The P/E ratio of Glenmark Pharmaceuticals Ltd is 44.87 times as on 05-Jun-2026, a 0 premium to its peers’ median range of 44.87 times.
The P/B ratio of Glenmark Pharmaceuticals Ltd is 5.81 times as on 05-Jun-2026, a 42 premium to its peers’ median range of 4.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
41.50
|
4.92
|
|
2024
|
0.00
|
3.45
|
|
2023
|
44.14
|
1.39
|
|
2022
|
13.25
|
1.38
|
|
2021
|
13.51
|
1.86
|
What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?
The 52-week high and low of Glenmark Pharmaceuticals Ltd are Rs 2,474.00 and Rs 1,589.00 as of 08-Jun-2026.
What is the market cap of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a market capitalisation of ₹ 61,111 Cr as on 05-Jun-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Glenmark Pharmaceuticals Ltd?
Before investing in Glenmark Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.